Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Knight TherapeuticsTSX:GUD +0.31%73 3-Year EBITDA Growth Rate is 40.20% as of Jun. 2026, which is 276% above its 10-year median of 10.70. GuruFocus rates TSX:GUD with a GF Score™ of 73/100 and a GF Value™ of C$9.26 (Fairly Valued). The stock has 4 warning signs investors should review. Among 808 Drug Manufacturers companies, Knight Therapeutics ranks better than 85.15% on this metric.
During the past 12 months, Knight Therapeutics's average EBITDA Per Share Growth Rate was 89.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 40.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Knight Therapeutics was 40.20% per year. The lowest was -9.40% per year. And the median was 10.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Knight Therapeutics 3-Year EBITDA Growth Rate Related Terms
TSX:GUD vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 40.20% mean?
Knight Therapeutics (TSX:GUD) has a 3-Year EBITDA Growth Rate of 40.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Knight Therapeutics and its competitors. This is 276% above median its historical median of 10.70. According to the industry distribution chart, Knight Therapeutics ranks #120 out of 808 companies in the Drug Manufacturers industry, placing it in the top 14.9%.
Is Knight Therapeutics' 3-Year EBITDA Growth Rate too high?
Knight Therapeutics' current 3-Year EBITDA Growth Rate of 40.20% is 276% above median its 10-year median of 10.70. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Knight Therapeutics' value of 40.20% is 351.7% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #120 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Knight Therapeutics has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #120 out of 808 companies for 3-Year EBITDA Growth Rate. This places Knight Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Knight Therapeutics' value of 40.20% is 351.7% above this benchmark. While the company's 10-year median is 10.70 vs. the industry median of 8.90, Knight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current 3-Year EBITDA Growth Rate of 40.20% is 351.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current 3-Year EBITDA Growth Rate is 40.20%, which is 276% above median its own 10-year median of 10.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Fairly Valued. The stock's GF Value™ is C$9.26, compared to a current price of C$9.67 — trading 4.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 40.20%, which is 276% above median its 10-year median of 10.70 and 351.7% above the Drug Manufacturers industry median of 8.90. Knight Therapeutics' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current 3-Year EBITDA Growth Rate is 40.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of C$9.67 is trading 4.4% above its estimated GF Value™ of C$9.26.
GuruFocus considers Knight Therapeutics to be Fairly Valued.
Key valuation signals for TSX:GUD:
3-Year EBITDA Growth Rate: 40.20% (276% above median its 10-year median of 10.70)
GF Value™: C$9.26 vs. price of C$9.67 (4.4% above fair value)
Industry Position: 351.7% above the Drug Manufacturers median (#120 of 808)
No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for TSX:GUD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:GUD has been successfully added to your 
